CompoAtlas

ORGASM GLOW - Sex au naturel

Food supplement declared in France, declaration No 2022-2-1245, decision dated 24 February 2022

ORGASM GLOW - Sex au naturel, from Bijoux indiscrets SL, is a food supplement declared in France. Status: declared in France, may be marketed. Main ingredients: Withania somnifera 110 mg per day, Tribulus terrestris 110 mg per day, Turnera diffusa 95 mg per day, Zinc, Arginine. 2 rules of use apply to its ingredients (limits and warnings).

Brand
not provided
Food business operator placing the product on the market
Bijoux indiscrets SL
Status
Declared in France, may be marketed: the authorities did not object to the declaration (this is neither an authorisation nor a safety assessment)
Form
Capsule
Daily dose
1 gélule
Intended populations
Men, Women
Not recommended (according to the manufacturer)
Adolescents (under 18), Breastfeeding women, History of breast cancer, Pregnant women, Taking anticoagulants, Taking diabetes medication, Taking blood pressure medication
Objectives stated by the manufacturer (these are not authorised claims)
Sexual vitality

Declaration 324929, procedure Article 15. Compl'Alim, food supplement declarations (France), retrieved 15 November 2026.

Declared composition

Plants

PlantPartPreparationPer day
Withania somnifera (L.) DunalRacineExtrait sec hydroalcoolique110 mg
Tribulus terrestris L.FruitExtrait sec hydroalcoolique110 mg
Turnera diffusa Willd. ex Schult.FeuilleExtrait sec hydroalcoolique95 mg

Other active ingredients

NamePer day
Argininenot declared

Vitamins and minerals

Compl'Alim does not publish vitamin and mineral doses. The references below help you read the product label: EFSAEuropean Food Safety Authority. safety limit for adults and maximum dose set in France per product (Order of 9 May 2006, not revised since November 2006).

Declared formNutrientEFSA limit, adults Maximum dose in France
zinc oxideZinc25 mg15 mg

Additives

E464, E460, E341, E470b, E551

Other ingredients

amidon de maïs

List from the declaration, administrative decision dated (Compl'Alim, food supplement declarations (France)).

Photograph the packaging

Label warnings

CONSULTEZ VOTRE MÉDECIN EN CAS DE PRISE SIMULTANÉE D'ANTICOAGULANTS, ANTIDIABÉTIQUES ET ANTIHYPERTENSEURS. NON RECOMMANDÉ PENDANT LA GROSSESSE ET L'ALLAITEMENT, AINSI QU'AUX MOINS DE 21 ANS. NE PAS DÉPASSER LA DOSE JOURNALIÈRE EXPRESSÉMENT RECOMMANDÉE. GARDER HORS DE LA PORTÉE DES ENFANTS. LES COMPLÉMENTS ALIMENTAIRES NE DOIVENT PAS SE SUBSTITUER À UN RÉGIME VARIÉ ET ÉQUILIBRÉ ET UN MODE DE VIE SAIN. UTILISATION DÉCONSEILLÉE CHEZ LES FEMMES AYANT DES ANTÉCÉDENTS PERSONNELS OU FAMILIAUX DE CANCER DU SEIN.

Regulatory points

This information reproduces the manufacturer's declaration to the administration (DGAL). It does not say whether the product is effective and does not replace advice from a doctor or pharmacist, particularly during pregnancy or when taking medication.

Official warnings (Health Canada)

Health Canada publishes warnings on these ingredients:

  • Withania somnifera (L.) Dunal
    Read the warning, when it applies and the studies cited

    ASHWAGANDHA - WITHANIA SOMNIFERA

    Route of administration: Oral

    Cautions and warnings

    Condition of application: General debility; Memory enhancement; Adaptogen; Restlessness/nervousness.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Condition of application: All products.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (Upton 2000; McGuffin et al. 1997).

    Sources cited by Health Canada (3)
    • McGuffin M, Hobbs C, Upton R, Goldberg A, editors. American Herbal Products Association's Botanical Safety Handbook. Boca Raton (FL): CRC Press, LLC; 1997.
    • Upton R, editor. American Herbal Pharmacopoeia and Therapeutic Compendium: Ashwagandha Root (Withania somnifera) - Standards of Analysis, Quality Control, and Therapeutics. Santa Cruz (CA): American Herbal Pharmacopoeia; 2000.
    • Berardi RR, DeSimone EM, Newton GD, Oszko MA, Popovich NG, Rollins CJ, Shimp LA, Tietze K, éditeurs. Handbook of Nonprescription Drugs: An Interactive Approach to Self-Care, 13e édition. Washington (DC) : American Pharmaceutical Association; 2002.

    When using this product exercise caution if you drive or use machinery as you may experience drowsiness (Berardi et al. 2002).

    Sources cited by Health Canada (3)
    • Berardi RR, DeSimone EM, Newton GD, Oszko MA, Popovich NG, Rollins CJ, Shimp LA and Tietze KJ, editors. Handbook of Nonprescription Drugs: An Interactive Approach to Self-Care, 13th edition. Washington (DC): American Pharmaceutical Association; 2002.
    • McGuffin M, Hobbs C, Upton R, Goldberg A, éditeurs. American Herbal Products Association's Botanical Safety Handbook. Boca Raton (FL) : CRC Press, LLC; 1997.
    • Upton R, éditeur. Ashwagandha Root, Withania somnifera Analytical, Quality Control, And Therapeutic Monograph. Santa Cruz (CA) : American Herbal Pharmacopoeia and Therapeutic Compendium; 2000.

    Health Canada monograph dated 28 February 2025

  • Tribulus terrestris L.
    Read the warning, when it applies and the studies cited

    TRIBULUS - TRIBULUS TERRESTRIS

    Route of administration: Oral

    Cautions and warnings

    Condition of application: All products except Vrsya (aphrodisiac for men).

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant (Chen and Chen 2004).

    Sources cited by Health Canada (1)
    • Chen JK, Chen TT. Chinese Medical Herbology and Pharmacology. Crampton L, editor. City of Industry (CA): Art of Medicine Press Inc.; 2004.

    Condition of application: Traditional Chinese Medicine.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have qi or blood deficiency (Bensky et al. 2004).

    Sources cited by Health Canada (1)
    • Bensky D, Clavey S, Toger E, Gamble A, editors. Chinese Herbal Medicine Materia Medica. 3rd edition. Seattle (WA): Eastland Press Inc; 2004.

    Contraindications

    Condition of application: Traditional Chinese Medicine.

    Do not use if you have low blood pressure or liver deficiency (Bensky et al. 2004; Chen and Chen 2004).

    Sources cited by Health Canada (2)
    • Bensky D, Clavey S, Toger E, Gamble A, editors. Chinese Herbal Medicine Materia Medica. 3rd edition. Seattle (WA): Eastland Press Inc; 2004.
    • Chen JK, Chen TT. Chinese Medical Herbology and Pharmacology. Crampton L, editor. City of Industry (CA): Art of Medicine Press Inc.; 2004.

    Known adverse reactions

    Condition of application: All products.

    Stop use if hypersensitivity/allergy occurs (Bensky et al. 2004)

    Sources cited by Health Canada (1)
    • Bensky D, Clavey S, Toger E, Gamble A, editors. Chinese Herbal Medicine Materia Medica. 3rd edition. Seattle (WA): Eastland Press Inc; 2004.

    Condition of application: All products except Mutrala (diuretic).

    When using this product diuretic effect may occur.

    Health Canada monograph dated 29 May 2026

  • Arginine
    Read the warning, when it applies and the studies cited

    L-ARGININE

    Route of administration: Oral

    Cautions and warnings

    Condition of application: All products.

    Ask a health care practitioner/health care provider/health care professional/doctor/ physician before use if you are pregnant or breastfeeding.

    Condition of application: Improvement in exercise capacity in individuals with stable CVD.

    Ask a health care practitioner/health care provider/health care professional/doctor/ physician if your symptoms worsen.

    Applies to products providing more than 0.42 g of L-Arginine, per day.

    Ask a health care practitioner/health care provider/health care professional/doctor/ physician before use if you have a cardiovascular disease and are attempting an increase in physical activity (Doutreleau et al. 2010; Doutreleau et al. 2006; Schulman et al. 2006; Goldman and Ausiello 2004; Nagaya et al. 2001; Bednarz et al. 2000; Ceremużyński et al. 1997; Rector et al. 1996).

    Sources cited by Health Canada (7)
    • Bednarz B, Wolk R, Chamiec T, Herbaczyńska-Cedro K, Winek D, Ceremużyński L. Effects of oral L-arginine supplementation on exercise-induced QT dispersion and exercise tolerance in stable angina pectoris. International Journal of Cardiology 2000;75(2-3):205-210. PubMed Randomised trial
    • Ceremużyński L, Chamiec T, Herbaczyńska-Cedro K. Effect of supplemental oral L-arginine on exercise capacity in patients with stable angina pectoris. The American Journal of Cardiology 1997;80(3):331-333. PubMed Randomised trial
    • Doutreleau S, Rouyer O, Di Marco P, Lonsdorfer E, Richard R, Piquard F, Geny B. L-Arginine supplementation improves exercise capacity after a heart transplant. American Journal of Clinical Nutrition. 2010. Doi: 10.3945/ajcn.2009.27881. DOI
    • Doutreleau S, Mettauer B, Piquard F, Rouyer O, Schaefer A, Lonsdorfer J., Beny B. Chronic L-Arginine Supplementation Enhances Endurance Exercise Tolerance in Heart Failure Patients. International Journal of Sports Medicine 2006;27(7):567-572. PubMed
    • Nagaya N, Uematsu M, Oya H, Sato N, Sakamaki F, Kyotani S, Ueno K, Nakanishi N, Yamagishi M, Miyatake K. Short-term oral administration of L-arginine improves hemodynamics and exercise capacity in patients with precapillary pulmonary hypertension. American Journal of Respiratory and Critical Care Medicine 2001;163(4):887-891. PubMed Randomised trial
    • Rector TS, Bank AJ, Mullen KA, Tschumperlin LK, Sih R, Pillai K, Kubo SH. Randomized, double-blind, placebo-controlled study of supplemental oral –arginine in patients with heart failure. Circulation 1996;93(12):2135-2141. PubMed Randomised trial
    • Schulman SP, Becker LC, Kass DA, Champion HC, Terrin ML, Forman S, Ernst KV, Kelemen MD, Townsend SN, Capriotti A, Hare JM, Gerstenblith G. L-Arginine therapy in acute myocardial infarction: the vascular interaction with age in myocardial infarction (VINTAGE MI) randomised clinical trial. Journal of American Medical Association 2006;295(1):58-64. PubMed Randomised trial

    1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).

    Ask a health care practitioner/health care provider/health care professional/doctor/ physician before use if you are taking medication for cardiovascular diseases, erectile dysfunction, and/or blood thinners (Huynh et al. 2002; Parker et al. 2002; Siani et al. 2000; Adams et al. 1995).

    Sources cited by Health Canada (4)
    • Adams MR, Forsyth CJ, Jessup W, Robinson J, Celermajer DS. Oral L-arginine inhibits platelet aggregation but does not enhance endothelium-dependent dilation in healthy young men. Journal of the American College of Cardiology 1995;26(4):1054-1061. PubMed Randomised trial
    • Huynh NT, Tayek JA. Oral arginine reduces systemic blood pressure in type 2 diabetes: Its potential role in nitric oxide generation. American College of Nutrition 2002;21(5):422-427. PubMed Clinical trial
    • Parker JO, Parker JD, Caldwell RW, Farrell B, Kaesemeyer WH. The effect of supplemental L-arginine on tolerance development during continuous transdermal nitroglycerin therapy. Journal of the American College of Cardiology 2002;39(7):1199-1203. PubMed Randomised trial
    • Siani A, Pagano E, Iacone R, Iacoviello L, Scopacasa F, Strazzullo P. Blood pressure and metabolic changes during dietary L-arginine supplementation in humans. American Journal of Hypertension 2000;13(5):547-551. PubMed Randomised trial

    Contraindications

    Applies to products providing more than 9 g of L-Arginine, per day.

    Do not use if you have had a heart attack/myocardial infarction (Sun et al. 2009; Schulman et al. 2006; Bednarz et al. 2005).

    Sources cited by Health Canada (3)
    • Bednarz B, Jaxa-Chamiec T, Maciejewski P, Szpajer M, Janik K, Gniot J, Kawka-Urbanek T, Drozdowska D, Gessek J, Laskowski H. Efficacy and safety of oral L-arginine in acute myocardial infarction. Results of the multicenter, randomized, double-blind, placebo-controlled ARAMI pilot trial. Kardiol Pol. 2005;62(5):421-427. PubMed Randomised trial
    • Schulman SP, Becker LC, Kass DA, Champion HC, Terrin ML, Forman S, Ernst KV, Kelemen MD, Townsend SN, Capriotti A, Hare JM, Gerstenblith G. L-Arginine therapy in acute myocardial infarction: the vascular interaction with age in myocardial infarction (VINTAGE MI) randomised clinical trial. Journal of American Medical Association 2006;295(1):58-64. PubMed Randomised trial
    • Sun T, Zhou WB, Luo XP, Tang YL, Shi HM. Oral L-arginine supplementation in acute myocardial infarction therapy: a meta-analysis of randomized controlled trials. Clin Cardiol. 2009;32(11):649-652. PubMed Meta-analysis

    Known adverse reactions

    Applies to products providing more than 9 g of L-Arginine, per day.

    When using this product you may experience gastrointestinal discomfort/disturbances (Grimble 2007; Evans et al. 2004; IOM 2005; Clarkson et al. 1996).

    Sources cited by Health Canada (4)
    • Clarkson P, Adams MR, Powe AJ, Donald AE, McCredie R, Robinson J, McCarthy SN, Keech A, Celermajer DS, Deanfield JE. Oral L-arginine endothelium-dependent dilation in hypercholesterolemic young adults. Journal of Clinical Investigation 1996;97(8):1989-1994. PubMed Randomised trial
    • Evans WR, Fernstrom JD, Thompson J, Morris SM Jr, Kuller LH. Biochemical responses of healthy subjects during dietary supplementation with L-arginine. Journal of Nutritional Biochemistry 2004;15(9):534-539. PubMed
    • Grimble GK. Adverse gastrointestinal effects of arginine and related amino acids. The Journal of Nutrition 2007;137(6 Suppl 2):1693S-1701S. PubMed Review article
    • IOM 2005: Institute of Medicine. Panel on Dietary Reference Intakes for Electrolytes and Water, and the Standing Committee on the Scientific Evaluation of Dietary Reference Intakes, Food and Nutrition Board, Institute of Medicine. Dietary Reference Intakes for Water, Potassium, Sodium, Chloride, and Sulfate. Washington (DC): National Academies Press; 2005.

    Health Canada monograph dated 25 July 2025

They concern the ingredient, not this product or its dose. They do not replace medical advice.

Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.

Cite this page: CompoAtlas, “ORGASM GLOW - Sex au naturel: composition and regulation”, https://compoatlas.com/en/supplements/products/324929-orgasm-glow-sex-au-naturel, updated 15 November 2026.

List recorded in 2022. Photograph the packaging to check whether it has changed.

Enter to analyse, Shift+Enter for a new line